Action 1ZL ZAI LAB LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Zai Lab Limited Deutsche Boerse AG

Actions

1ZL

US98887Q1040

Temps réel estimé Tradegate
Autres places de cotation
 13:24:54 05/07/2024 		Varia. 5j. Varia. 1 janv.
16,05 EUR +4,90% Graphique intraday de Zai Lab Limited -4,97% -37,30%
27/06 Un initié de Zai Lab a vendu des actions pour une valeur de 428 532 $, selon un récent dépôt auprès de la SEC MT
20/06 Zai Lab attribue des ADS à des directeurs indépendants dans le cadre d'un plan d'incitation MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing
Zai Lab : Argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropath
Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading
Zai Lab Limited Announces Executive Changes, Effective June 30, 2024
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
Tech, Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower
Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Zai Lab and Innoviva Specialty Therapeutics Announces NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading
Zai Lab Announces Participation in May and June Investor Conferences
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ZLAB
  4. Action 1ZL
  5. Actualités Zai Lab Limited
  6. Autres langues